Letolizumab

Letolizumab (INN;[1] development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

Letolizumab

Monoclonal antibody
Type	Single-chain variable fragment
Source	Humanized (from mouse)
Target	tumor necrosis factor related activation protein
Clinical data
Other names	BMS-986004
ATC code	none
Identifiers
CAS Number	1450981-87-9
ChemSpider	none
UNII	449MIE2SD6
KEGG	D11122
Chemical and physical data
Formula	C1734H2688N466O538S10
Molar mass	38991.90 g·mol^−1

This drug was developed by Bristol-Myers Squibb.[2]

References

1. World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
2. Statement On A Nonproprietary Name Adopted By The USAN Council - Letolizumab, American Medical Association.